title: MyCartis NV.
abstract: MyCartis NV, a new player on the clinical and translational research market, aims at revolutionizing current healthcare systems. These are mostly based on treating the diseased rather than on caring better and longer for the healthy. The 'one size fits all' model is no longer sufficient and is unsustainable in the long run. Although it comes very scattered, today's access to molecular information has the potential to make healthcare more personal and effective, shifting it from treating diseases to improving quality of life. MyCartis wants to contribute to this process by developing broadly available next generation multiplex biomarker analysis solutions both at the technical and content levels. The Evalution™ platform provides a 'one technology fits all' solution to enable researchers to validate their biomarkers and assay providers to utilize them, no matter their physical nature: multiplexing in its true sense. The ability to quantify different types of markers on a single platform will help produce more comprehensive and coherent multiplex datasets, which will facilitate the integration into syndromic assay formats.
authors.affiliation: MyCartis Belgium, Technologiepark 4, B-9052 Zwijnaarde, Belgium.
authors.forename: Wouter
authors.initials: W
authors.lastname: Laroy
authors.forename: Paul
authors.initials: P
authors.lastname: Ladestein
mesh_terms: D001530:Belgium; D015415:Biomarkers / Q000032:analysis*; D019411:Clinical Laboratory Techniques / Q000295:instrumentation* / Q000379:methods; D006801:Humans; D013557:Switzerland; D013672:Technology / Q000295:instrumentation* / Q000379:methods; D057170:Translational Research, Biomedical / Q000295:instrumentation* / Q000379:methods
chemical_list: D015415:Biomarkers
keywords: Evalution™; biomarkers; diagnostics; multiplex technology; personalized healthcare